Introduction: Iron deficiency is the most common cause of anemia in both sexes, although it is more common in women. Intravenous (IV) iron replacement is preferred in patients who cannot tolerate oral treatment or when iron stores need to be replenished rapidly. In this study, we wanted to share the ferric carboxymaltose (FCM) desensitization protocol that we self-created and successfully applied. Methods: This retrospective cross-sectional study included patients with a history of hypersensitivity reactions (HSRs) to IV or oral iron replacement and patients who were planned to receive IV iron replacement but were referred to the allergy clinic because of have risk factors (atopic diseases, history of HSR to other drugs, high serum tryptase levels, etc.) for HSRs. Before desensitization, some of the patients underwent skin tests (skin prick test and intradermal test) with FCM, and the results were recorded. Skin tests were not performed in patients with a history of drug use (antihistamine, systemic steroid, omalizumab, etc.) that affected the results of skin tests. All patients underwent a one-bag 8-step desensitization protocol with 500 mg FCM and were observed for 2 h after desensitization. Results: A total of 15 patients (14 females and 1 male) with a mean age of 41.13 ± 11.18 years were included in the study. When the patients were evaluated in terms of the risk of allergic reactions according to their clinical history, 8 patients had a history of anaphylaxis with iron preparations (FCM, n = 4; ferric hydroxide sucrose, n = 2; iron [II] glycine sulfate, n = 1; and iron [III] hydroxide polymaltose, n = 1), and 7 patients had a history of HSR other than anaphylaxis with iron preparations (urticaria, n = 6 [FCM, n = 2; iron (II) glycine sulfate, n = 2; and iron (III) hydroxide polymaltose, n = 2] and urticaria + angioedema [ferric hydroxide sucrose, n = 1]). Desensitization was successfully completed in all patients. No HSR was observed during or after the procedure in any of the patients. Conclusion: IV iron replacement is a very effective method, especially in cases where iron stores need to be replenished more rapidly. In patients with a history of iron HSR or at risk of developing HSR, replacement can be safely performed without an allergic reaction with successful desensitization protocols.

1.
Jimenez
K
,
Kulnigg-Dabsch
S
,
Gasche
C
.
Management of iron deficiency anemia
.
Gastroenterol Hepatol
.
2015
;
11
(
4
):
241
50
.
2.
Auerbach
M
,
Gafter Gvili
A
,
Mac Dougall
IC
.
Intravenous iron: a framework for changing the management of iron deficiency
.
Lancet Hematol
.
2020
;
7
(
4
):
e342
e350
.
3.
Szebeni
J
,
Fishbane
S
,
Hedenus
M
,
Howaldt
S
,
Locatelli
F
,
Patni
S
.
Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management
.
Br J Pharmacol
.
2015
;
172
(
21
):
5025
36
.
4.
Caimmi
S
,
Crisafulli
G
,
Franceschini
F
,
Liotti
L
,
Bianchi
A
,
Bottau
P
.
Hypersensitivity to intravenous iron preparations
.
Children
.
2022
;
9
(
10
):
1473
.
5.
Neiser
S
,
Koskenkorva
TS
,
Schwarz
K
,
Wilhelm
M
,
Burckhardt
S
.
Assessment of dextran antigenicity of intravenous iron preparations with Enzyme-Linked Immunosorbent Assay (ELISA)
.
Int J Mol Sci
.
2016
;
17
(
7
):
1185
.
6.
Macdougall
IC
,
Vernon
K
.
Complement activation-related pseudo-allergy: a fresh look at hypersensitivity reactions to intravenous iron
.
Am J Nephrol
.
2017
;
45
(
1
):
60
2
.
7.
Novey
HS
,
Pahl
M
,
Haydik
I
,
Vaziri
ND
.
Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis
.
Ann Allergy
.
1994
;
72
(
3
):
224
8
.
8.
Fleming
LW
,
Stewart
WK
,
Parratt
D
.
Dextran antibodies, complement conversion and cir- culating immune complexes after intra- venous iron dextran therapy in dialysed patients
.
Nephrol Dial Transplant
.
1992
;
7
(
1
):
35
9
.
9.
Szebeni
J
,
Baranyi
L
,
Sávay
S
,
Bodó
M
,
Milosevits
J
,
Alving
CR
.
Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function
.
Am J Physiol Heart Circ Physiol
.
2006
290
3
H1050
8
.
10.
Chertow
GM
,
Mason
PD
,
Vaage-Nilsen
O
,
Ahlmen
J
.
Update on adverse drug events associated with parenteral iron
.
Nephrol Dial Transplant
.
2006
;
21
(
2
):
378
82
.
11.
Povesi Dascola
C
,
Caffarelli
C
.
Exercise-induced anaphylaxis: a clinical view
.
Ital J Pediatr
.
2012
;
38
:
43
.
12.
Steveling-Klein
EH
,
Mateluna
CM
,
Meienberg
A
,
Hartmann
K
,
Bircher
A
,
Scherer Hofmeier
K
.
Management of hypersensitivity reactions to non-dextran iron products: new insights into predisposing risk factors
.
J Allergy Clin Immunol Pract
.
2021
;
9
(
6
):
2406
14.e2
.
13.
Rampton
D
,
Folkersen
J
,
Fishbane
S
,
Hedenus
M
,
Howaldt
S
,
Locatelli
F
.
Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management
.
Haematologica
.
2014
;
99
(
11
):
1671
6
.
14.
Aberer
W
,
Bircher
A
,
Romano
A
,
Blanca
M
,
Campi
P
,
Fernandez
J
.
Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations
.
Allergy
.
2003
;
58
(
9
):
854
63
.
15.
Kang
SY
,
Seo
J
,
Kang
HR
.
Desensitization for the prevention of drug hypersensitivity reactions
.
Korean J Intern Med
.
2022
;
37
(
2
):
261
70
.
16.
Chapman
E
,
Leal
D
,
Alvarez
L
,
Duarte
M
,
García
E
.
Two case reports of desensitization in patients with hypersensitivity to iron
.
World Allergy Organ J
.
2017
;
10
(
1
):
38
.
17.
Di Girolamo
A
,
Albanesi
M
,
Loconte
F
,
Di Bona
D
,
Caiaffa
MF
,
Macchia
L
.
Desensitization in iron product allergy
.
Acta Haematol
.
2020
;
143
(
5
):
496
9
.
18.
European Medicines Agency
New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines
European Medicines Agency
2013
. EMA/579491/2013:1-3. Available from: https://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500151308.pdf.
19.
Castells
M
,
Sancho-Serra
MC
,
Simarro
M
.
Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization
.
Cancer Immunol Immunother
.
2012
;
61
(
9
):
1575
84
.
20.
Castells
MC
,
Tennant
NM
,
Sloane
DE
,
Hsu
FI
,
Barrett
NA
,
Hong
DI
.
Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases
.
J Allergy Clin Immunol
.
2008
;
122
(
3
):
574
80
.
21.
Sloane
D
,
Govindarajulu
U
,
Harrow-Mortelliti
J
,
Barry
W
,
Hsu
FI
,
Hong
D
.
Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies
.
J Allergy Clin Immunol Pract
.
2016
;
4
(
3
):
497
504
.
22.
Vetter
MH
,
Khan
A
,
Backes
FJ
,
Bixel
K
,
Cohn
DE
,
Copeland
LJ
.
Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions
.
Gynecol Oncol
.
2019
;
152
(
2
):
316
21
.
23.
Hong
D
,
Bankova
L
,
Cahill
K
,
Kyin
T
,
Castells
M
.
Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies
.
Expert Rev Clin Immunol
.
2012
;
8
(
1
):
43
52
; quiz 53-4.
24.
Vidal
C
,
Méndez-Brea
P
,
López-Freire
S
,
Bernárdez
B
,
Lamas
MJ
,
Armisén
M
.
A modified protocol for rapid desensitization to chemotherapy agents
.
J Allergy Clin Immunol Pract
.
2016
;
4
:
1003
5
.
25.
Özdedeoğlu
Ö
,
Aksu
K
,
Aydoğan
B
,
Ateş
H
,
Buhari
G
,
Kalkan
İ
.
Successful desensitization with ferric carboxymaltose
.
Asthma Allergy Immunol
.
2020
;
18
(
1
):
51
3
.
26.
Montandon
SV
,
Fajt
ML
,
Petrov
AA
.
A safe and novel desensitization protocol with Ferric Carboxymaltose to treat iron deficiency anemia
.
Curr Drug Saf
.
2016
;
11
(
2
):
145
8
.
27.
Pagani
M
,
Bavbek
S
,
Alvarez-Cuesta
E
,
Berna Dursun
A
,
Bonadonna
P
,
Castells
M
.
Hypersensitivity reactions to chemotherapy: an EAACI position paper
.
Allergy
.
2022
;
77
(
2
):
388
403
.
28.
Szebeni
J
.
Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals
.
Mol Immunol
.
2014
;
61
(
2
):
163
73
.
29.
Altman
LC
,
Petersen
PE
.
Successful prevention of an anaphylactoid reaction to iron dextran
.
Ann Intern Med
.
1988
;
109
(
4
):
346
7
.
30.
Monaghan
MS
,
Glasco
G
,
St John
G
,
Bradsher
RW
,
Olsen
KM
.
Safe administration of iron dextran to a patient who reacted to the test dose
.
South Med J
.
1994
;
87
(
10
):
1010
2
.
31.
Hickman
MA
,
Bernstein
IL
,
Palascak
JE
.
Successful administration of iron dextran in a patient who experienced a life threatening reaction to intravenous iron dextran
.
Ann Allergy Asthma Immunol
.
2000
;
84
(
2
):
262
3
.
32.
Rodríguez-Jiménez
B
,
Domínguez-Ortega
J
,
Nuñez-Acevedo
B
,
Cava-Sumner
B
,
Kindelan-Recarte
C
,
Montojo Guillén
C
.
Rapid iron desensitization after generalized urticaria and facial angioedema
.
J Investig Allergol Clin Immunol
.
2014
;
24
(
1
):
69
71
.
You do not currently have access to this content.